Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04570085 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of CAFfeine on Cognition in Alzheimer's Disease

Study acronym: CAFCA
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 2026 to Dec 2027v6
  2. Primary and study completion dates: Nov 2024 to Nov 2026v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 16 to 17
    • Start date changed from estimate of Nov 2021 to Mar 1, 2021
    v4
  4. Primary and study completion dates: Nov 2023 to Nov 2024
    • Start date: Nov 2020 to Nov 2021
    v3
  5. Start date: Sep 2020 to Nov 2020
    • Primary and study completion dates: Sep 2023 to Nov 2023
    • Study title revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic stakes for our aging societies. There is currently no curative treatment available. Coffee is a complex beverage with psychostimulant properties whose main effective element, caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological properties enable its use like an Alzheimer's disease symptomatic treatment. Its supposed benefits mustn't obscure anxiety and insomnia caffeine effect at large dose, which Alzheimer's patients might be more vulnerable. The main study objective is to evaluate placebo-controlled caffeine efficacy (30 treatments weeks) on cognitive decline in Alzheimer's disease dementia at beginning to moderate stage (MMSE 16-24).
Trial Details
NCT Number NCT04570085
Lead Sponsor University Hospital, Lille
Collaborators: Groupement Interrégional de Recherche Clinique et d'Innovation, Laboratory of excellence DISTALZ, Région Nord-Pas de Calais, France, Meo coffee
Conditions
(from sponsor)		 Alzheimer Disease
Related terms Alzheimer Disease, Cognitive Dysfunction
Enrollment 248 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov